Hyaluronic acid derivative or salt with nitric oxide and active oxygen dual response characteristic as well as preparation method and application of hyaluronic acid derivative or salt

By performing structural modification and esterification reaction on hyaluronic acid molecules, hyaluronic acid derivatives with dual response characteristics of nitric oxide and reactive oxygen species were formed, which solved the short retention time of sodium hyaluronic acid in the body and the inability to remove inflammatory factors. Problem, achieving intelligent response and drug delivery, enhancing lubricating, anti-inflammatory and antioxidant effects.

CN118909159AActive Publication Date: 2024-11-08CHINA PHARM UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410969061.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-08
Estimated Expiration
2044-07-19

AI Technical Summary

Technical Problem

The existing sodium hyaluronate is easily degraded and absorbed in the body, and has a short residence time, so it cannot effectively remove inflammatory factors such as reactive oxygen species and nitric oxide, affecting the efficacy.

Method used

By modifying the hyaluronic acid molecules in a structural manner, introducing branched and crosslinked structures, forming hyaluronic acid derivatives or salts with dual response characteristics of nitric oxide and reactive oxygen species, and esterification reactions are carried out using condensing agents and vitamin C. Extend retention time in vivo and enable intelligent response and drug delivery.

Benefits of technology

Prolong the retention time of hyaluronic acid and its salts, achieve intelligent response and removal of high-concentration inflammatory factors in the microenvironment, enhance lubricating, anti-inflammatory, antioxidant and controlled release characteristics, and improve therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909159A_ABST
    Figure CN118909159A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of medicinal chemistry, and particularly relates to a hyaluronic acid derivative or salt with nitric oxide and active oxygen dual response characteristics and a preparation method and application thereof. The preparation method comprises the following steps: preparing HA-o-phenylenediamine-maleic acid-Vc through chemical grafting of hyaluronic acid; the polymer has environmental response characteristics, good biocompatibility, excellent injection characteristics and good biological environmental responsiveness, can perform intelligent response according to the concentration of active oxygen and nitric oxide in the environment and remove the active oxygen and nitric oxide, reduces the overhigh concentration level of adverse factors in the environment, has excellent stability, and can be used in the fields of intelligent delivery of drugs and cosmetics.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical chemistry, and specifically relates to a hyaluronic acid derivative or salt having dual response characteristics to nitric oxide and active oxygen, and a preparation method and application thereof. Background Art

[0002] Hyaluronic acid (HA) is an acidic mucopolysaccharide, also known as hyaluronic acid. It is an unbranched high-molecular glycosaminoglycan composed of N-acetylglucosamine and D-glucuronic acid disaccharide repeating units. It exists in the interstitial cells of animal tissues and the capsules of certain bacteria. It is an important component of the cell matrix and various tissues and has many important physiological functions. The unique viscoelasticity, biocompatibility and degradability of sodium hyaluronate make it widely used in the biomedical field, including as an adjuvant for ophthalmic surgery, an anti-adhesion agent after surgery, a skin wound healing and regeneration aid, a drug carrier, and a tissue engineering scaffold. In addition, the hydroxyl, carboxyl and other polar groups in the hyaluronate molecule can form hydrogen bonds with water molecules to bind a large amount of water, with a significant water retention effect. As a gel-like substance containing water, it has excellent performance in maintaining the viscoelasticity of biological tissues (especially skin tissues) and moisturizing biological tissues. It is widely used in the field of cosmetics for moisturizing, lubrication, anti-oxidation, and anti-inflammatory.

[0003] Hyaluronic acid has a unique molecular structure and physical and chemical properties, and it plays a key role in joint lubrication. As an important component of synovial fluid, hyaluronic acid can promote the production of synovial fluid and act as a lubricant and shock absorber in the joint structure. It can reduce friction between joints and enhance joint lubrication, thereby protecting joints and reducing wear during joint movement. With age, the content of hyaluronic acid in the human body will gradually decrease, which may lead to insufficient joint lubrication and increase the risk of joint wear. In order to maintain joint health, hyaluronic acid or its salts, such as sodium hyaluronate, are widely used in the treatment of joint-related diseases. On the one hand, it can effectively lubricate joints, relieve symptoms such as joint pain and limited mobility, and has a certain effect on the treatment of diseases such as osteoarthritis. In addition, hyaluronic acid or its salts also have a certain anti-infection effect, which helps to improve conditions such as joint inflammation.

[0004] However, sodium hyaluronate is easily degraded and absorbed in the body, and has a short retention time (its half-life does not exceed 24 hours after injection into the skin or joints). It mainly achieves its anti-inflammatory effect through its moisturizing ability and its promotion of cell metabolism, but it has no ability to clear inflammatory factors in the inflammatory environment, and does not have the special function of clearing oxygen and nitric oxide (NO), which affects its efficacy and application. Summary of the invention

[0005] The purpose of the present invention is to solve the deficiencies in the prior art and to provide a hyaluronic acid derivative or salt having dual response characteristics to nitric oxide and reactive oxygen species, and a preparation method and application thereof.

[0006] In order to achieve the above object, the present invention is achieved through the following technical solutions:

[0007] In a first aspect, the present invention provides a hyaluronic acid derivative or salt having dual responses to nitric oxide and reactive oxygen species, wherein the structure of the hyaluronic acid derivative is shown in Formula I:

[0008]

[0009] The salt is a sodium salt, a potassium salt, a zinc salt or a calcium salt.

[0010] In a second aspect, the present invention provides a method for preparing a hyaluronic acid derivative or salt having dual responses to nitric oxide and reactive oxygen species, the method comprising the following steps:

[0011] Step S1, dissolving hyaluronic acid in water, adding methyl 3,4-diaminobenzoate and a condensing agent, stirring for 6 to 30 hours at a temperature of 10-50° C. to cause a condensation reaction, and after the reaction is completed, dialysis purification and freeze-drying to obtain the product HA-o-phenylenediamine; the condensing agent is 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, wherein the molar ratio of hyaluronic acid, methyl 3,4-diaminobenzoate, 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride is 1:1-3:1-4:1-4; the reaction formula is:

[0012]

[0013] Step S2, dissolving the product HA-o-phenylenediamine with a solvent, adding a solution of maleic anhydride dropwise, heating at a temperature of 25-60° C. for esterification reaction for 6-30 hours, and after the reaction is completed, dialyzing and freeze-drying to obtain the product HA-o-phenylenediamine-maleic acid; wherein the molar ratio of HA-o-phenylenediamine to maleic anhydride is 1:1-5; and the reaction formula is:

[0014]

[0015] Step S3, the product HA-o-phenylenediamine-maleic acid is dissolved with a solvent and water, a condensing agent and vitamin C are added, and a condensation reaction is carried out at a temperature of 10-50° C. for 6-30 hours by stirring. After the reaction is completed, the product HA-o-phenylenediamine-maleic acid-Vc is obtained by dialysis and freeze-drying; the condensing agent is 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, wherein the molar ratio of the product HA-o-phenylenediamine-maleic acid, 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, and vitamin C is 1:1-5:1-5:1-5; the reaction formula is:

[0016]

[0017] Furthermore, in step S2, the solvent is selected from one or more of dimethyl sulfoxide, dimethylformamide, and N-methylpyrrolidone.

[0018] In a third aspect, the present invention provides a composition comprising the hyaluronic acid derivative or salt.

[0019] The composition is in the form of a gel-like aqueous solution.

[0020] In a fourth aspect, the present invention provides a use of the hyaluronic acid derivative or salt in the preparation of cosmetics or medicines having lubricating, anti-inflammatory, antioxidant or moisturizing effects.

[0021] 1. The method of the present invention gives hyaluronic acid and its salts more functions, such as intelligently responding to high concentrations of adverse factors in the microenvironment and clearing the high concentration factors to exert a synergistic therapeutic effect.

[0022] 2. The present invention introduces side chains by grafting to form a cross-linked structure, thereby reducing the degradation rate of hyaluronic acid and its salts and prolonging the in vivo retention time.

[0023] 3. The branched chains introduced by the grafting of the present invention undergo structural changes in response to the environment, and at the same time complete the drug release, thereby achieving speed control after the drug is delivered to the target site and exerting a targeted release effect.

[0024] 4. After grafting modification, the existing natural properties such as biocompatibility, gel properties, transdermal absorption properties, etc. are retained, while the lubrication, anti-inflammatory, antioxidant and controlled release properties are enhanced.

[0025] 5. After grafting and modification, hyaluronic acid reduces the susceptibility of exposed hydroxyl groups to oxidation through the condensation of chemical bonds in Vc, and significantly improves the stability of antioxidant properties and the sustained-release characteristics of active oxygen scavenging.

[0026] The present invention has the following beneficial effects: (1) The present invention can be used for the treatment of arthritis or skin tissue and for drug delivery by structurally modifying the hyaluronic acid molecule. After being delivered to the target site, the hyaluronic acid derivative or its salt can realize intelligent response to the microenvironment and remove excessive reactive oxygen and inflammatory factors such as nitric oxide in the environment. As the introduced functional groups are consumed, the delivery carrier is gradually degraded and the drug is slowly released. The freed hyaluronic acid or its salt exerts lubricating, moisturizing, anti-inflammatory, anti-aging and other therapeutic effects, thereby realizing multiple therapeutic effects.

[0027] (2) The present invention prepares hyaluronic acid and its salts with environmental responsiveness, which have good biocompatibility, excellent injection properties, and good biological environmental responsiveness. They can intelligently respond to and remove the concentrations of reactive oxygen and nitric oxide in the environment, reduce the concentration level of excessively high adverse environmental factors, and have excellent stability. They can be used in the fields of intelligent drug delivery and cosmetics. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 : NMR characterization of hyaluronic acid grafted with vitamin C in the comparative example;

[0029] Figure 2 : Infrared spectrum characterization of hyaluronic acid grafted with vitamin C in the comparative example;

[0030] Figure 3 : NMR characterization of the grafted o-phenylenediamine and vitamin C hyaluronic acid in Example 1;

[0031] Figure 4 : NMR characterization of the hyaluronic acid grafted with o-phenylenediamine and vitamin C in Example 2;

[0032] Figure 5 : NMR characterization of hyaluronic acid grafted with o-phenylenediamine in Example 3;

[0033] Figure 6 : NMR characterization of the hyaluronic acid grafted with o-phenylenediamine and vitamin C in Example 3;

[0034] Figure 7 : Infrared spectrum characterization of hyaluronic acid grafted with o-phenylenediamine in Example 3;

[0035] Figure 8 : Infrared spectroscopic characterization of the grafted o-phenylenediamine and vitamin C hyaluronic acid in Example 3;

[0036] Fig. 9 : Infrared spectroscopic characterization of hyaluronic acid;

[0037] Fig.10: Viscosity and injectability of hyaluronic acid solutions of different concentrations (a. 20 mg / ml HA solution (left: EP tube inverted characterization, middle: vial tilted characterization, right: injectability characterization), b. 40 mg / ml HA solution (left: EP tube inverted characterization, middle: vial tilted characterization, right: injectability characterization), c. 60 mg / ml HA solution (left: EP tube inverted characterization, middle: vial tilted characterization, right: injectability characterization), d. 80 mg / ml HA solution (left: EP tube inverted characterization, middle: vial tilted characterization, right: injectability characterization), e. 100 mg / ml HA solution (left: EP tube inverted characterization, middle: vial tilted characterization, right: injectability characterization);

[0038] Fig.11 : Viscosity and injectability of hyaluronic acid (VHA) solution grafted with o-phenylenediamine and vitamin C (70 mg / ml VHA solution (left: EP tube inverted characterization, middle: vial tilted characterization, right:

[0039] Injectability characterization);

[0040] Fig.12 : Response and scavenging ability of grafted and blank hyaluronic acid to reactive oxygen species;

[0041] Fig.13 : Response and scavenging ability of grafted and blank hyaluronic acid to NO;

[0042] Fig.14 : Stability of active oxygen scavenging ability of grafted hyaluronic acid VHA and physical mixture of hyaluronic acid and Vc (n=3);

[0043] Fig.15 : Effects of hyaluronic acid grafted with o-phenylenediamine and vitamin C on RAW264.7 cell viability (n=3);

[0044] Fig.16 : Effects of hyaluronic acid grafted with o-phenylenediamine and vitamin C on MH7A cell viability (n=3);

[0045] Fig.17 :Griess method was used to detect the NO concentration level in RAW 264.7 cells polarized by LPS (n=3);

[0046] Fig.18 :Inverted fluorescence microscope was used to observe the NO fluorescence intensity in RAW 264.7 cells after LPS polarization treatment;

[0047] Fig.19 :Statistical analysis of fluorescence intensity of NO concentration in RAW 264.7 cells treated with LPS polarization;

[0048] Fig. 20 :Inverted fluorescence microscopy was used to observe the ROS fluorescence intensity in RAW 264.7 cells after LPS polarization treatment;

[0049] Fig.21 : Statistical analysis of fluorescence intensity of ROS concentration levels in RAW 264.7 cells treated with LPS polarization. DETAILED DESCRIPTION

[0050] The present invention is further described by way of the following examples, which do not limit the present invention in any way. Without departing from the technical solution of the present invention, any modification or change made to the present invention that is easily implemented by a person of ordinary skill in the art will fall within the scope of the claims of the present invention.

[0051] Grafting reaction design and preparation process:

[0052] (a) Hyaluronic acid (HA) is completely dissolved in water, wherein the ratio of HA to water (m / V) is 1:(50-200), methyl 3,4-diaminobenzoate, and two condensing agents, 1-hydroxybenzotriazole (HOBT) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), are added, wherein the molar ratio of hyaluronic acid, methyl 3,4-diaminobenzoate, HOBT and EDCI is 1:1-3:1-4:1-4; the mixture is stirred and reacted at a temperature of 10-50°C for 6-30 hours, dialyzed with a dialysis bag for 24-48 hours (changing the water 2-3 times), and freeze-dried to obtain a solid, namely HA-o-phenylenediamine (abbreviated as ODP-HA).

[0053] (b) The obtained solid HA-o-phenylenediamine is dissolved with DMSO (100V), and maleic anhydride is dissolved with 10V DMSO, and the maleic anhydride solution is added dropwise to the system, wherein the molar ratio of HA-o-phenylenediamine to maleic anhydride is 1:1-5. After the addition is completed, the temperature is raised to 20-60°C, and the reaction is carried out for 6-30 hours. The solution is dialyzed with a dialysis bag for 24-48 hours (changing the water 2-3 times), and the solid, i.e., HA-o-phenylenediamine-maleic acid, is lyophilized.

[0054] (c) The obtained solid HA-o-phenylenediamine-maleic acid is dissolved with DMSO (200V) and water (100V), and HOBT (1-5eq), EDCI (1-5eq), and vitamin C (Vc) (the amount of the feed is 1-5eq) are added, and the mixture is stirred at 10-40°C for 6-30h, dialyzed with a dialysis bag for 24-48h (changing the water 2-3 times), and freeze-dried to obtain a solid, namely HA-o-phenylenediamine-maleic acid-Vc (abbreviated as VHA).

[0055] Comparative Example:

[0056] Dissolve hyaluronic acid (HA) with DMSO (200V) and water (100V), add HOBT (1-5eq), EDCI (1-5eq), vitamin C (Vc) (feeding amount is 1-5eq), react at room temperature (preferably 10-40°C) with stirring for 6-30h, dialyze with a dialysis bag for 24-48h (change water 2-3 times), and freeze-dry to obtain a solid, i.e., hyaluronic acid-Vc (abbreviated as HA-Vc). The nuclear magnetic resonance spectrum shows a chemical shift of δ=4.6-4.7, which is the chemical shift of hydrogen (CH) on the Vc ring, indicating that VC and hyaluronic acid have successfully reacted. The nuclear magnetic resonance data are as follows: Figure 1 As shown in the infrared spectrum of hyaluronic acid grafted with vitamin C, it can be seen from the spectrum that 1650cm -1 ~1750cm -1 The C=O stretching vibration and C=C olefinic stretching vibration spectra of the ester group match the lactone and double bond structures in the Vc structure, such as Figure 2 shown.

[0057] Example 1

[0058] (a) Hyaluronic acid (HA) is completely dissolved in water, wherein the ratio of HA to water (m / V) is 1:(50-200), methyl 3,4-diaminobenzoate, and two condensing agents, 1-hydroxybenzotriazole (HOBT) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), are added, wherein the molar ratio of hyaluronic acid, methyl 3,4-diaminobenzoate, HOBT and EDCI is 1:1:1:1; the mixture is stirred at 20°C for 10 hours, dialyzed with a dialysis bag for 24 hours (changing the water 2-3 times), and freeze-dried to obtain a solid, namely HA-o-phenylenediamine (abbreviated as ODP-HA).

[0059] (b) The obtained solid HA-o-phenylenediamine was dissolved with DMSO (100V), and maleic anhydride was dissolved with 10V DMSO, and the maleic anhydride solution was added dropwise to the system, wherein the molar ratio of HA-o-phenylenediamine to maleic anhydride was 1:1. After the addition was completed, the temperature was raised to 35°C, and the reaction was carried out for 10 hours. The system was dialyzed with a dialysis bag for 24 hours (changing the water 2-3 times), and the solid was freeze-dried to obtain HA-o-phenylenediamine-maleic acid.

[0060] (c) The obtained solid HA-o-phenylenediamine-maleic acid is dissolved with DMSO (200V) and water (100V), and HOBT, EDCI, and vitamin C (Vc) are added, wherein the molar ratio of HA-o-phenylenediamine-maleic acid, HOBT, EDCI and vitamin C is 1:1:1:1, and the reaction is stirred at 20°C for 10 hours, dialyzed with a dialysis bag for 24 hours (changing the water 2-3 times), and freeze-dried to obtain a solid, namely HA-o-phenylenediamine-maleic acid-Vc (abbreviated as VHA).

[0061] Example 2

[0062] (a) Hyaluronic acid (HA) is completely dissolved in water, wherein the ratio of HA to water (m / V) is 1:(50-200), methyl 3,4-diaminobenzoate, and two condensing agents, 1-hydroxybenzotriazole (HOBT) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), are added, wherein the molar ratio of hyaluronic acid, methyl 3,4-diaminobenzoate, HOBT and EDCI is 1:2:2:2; the mixture is stirred at 30°C for 15 hours, dialyzed with a dialysis bag for 36 hours (changing the water 2-3 times), and freeze-dried to obtain a solid, namely HA-o-phenylenediamine (abbreviated as ODP-HA).

[0063] (b) The obtained solid HA-o-phenylenediamine was dissolved with DMSO (100V), and maleic anhydride was dissolved with 10V DMSO, and maleic anhydride solution was added dropwise to the system, wherein the molar ratio of HA-o-phenylenediamine to maleic anhydride was 1:4. After the addition was completed, the temperature was raised to 45°C, and the reaction was carried out for 15 hours. The system was dialyzed with a dialysis bag for 36 hours (changing the water 2-3 times), and the solid was freeze-dried to obtain HA-o-phenylenediamine-maleic acid.

[0064] (c) The obtained solid HA-o-phenylenediamine-maleic acid is dissolved with DMSO (200V) and water (100V), and HOBT, EDCI, and vitamin C (Vc) are added, wherein the molar ratio of HA-o-phenylenediamine-maleic acid, HOBT, EDCI and vitamin C is 1:4:4:4, and the reaction is stirred at 30°C for 15h, dialyzed with a dialysis bag for 36h (changing the water 2-3 times), and freeze-dried to obtain a solid, namely HA-o-phenylenediamine-maleic acid-Vc (abbreviated as VHA).

[0065] Example 3

[0066] Compared with Example 2,

[0067] In step (a), the molar ratio of hyaluronic acid, methyl 3,4-diaminobenzoate, HOBT and EDCI is 1:3:3:3; the reaction is stirred at 40° C. for 25 h, and dialyzed with a dialysis bag for 48 h (changing the water 2-3 times).

[0068] In step (b), the molar ratio of HA-o-phenylenediamine to maleic anhydride is 1:5. After the addition is completed, the temperature is raised to 55° C., the reaction is carried out for 25 hours, and the mixture is dialyzed in a dialysis bag for 48 hours (changing the water 2-3 times).

[0069] In step (c), the molar ratio of HA-o-phenylenediamine-maleic acid, HOBT, EDCI and vitamin C is 1:5:5:5, the reaction is stirred at 40°C for 25 hours, and the dialysis bag is used for 48 hours (the water is changed 2-3 times). Others are the same as in Example 2.

[0070] In Example 1, the product of step c was characterized by NMR: Figure 3As shown, the ratio of hyaluronic acid, o-phenylenediamine and Vc is close to 1:1:1.

[0071] In Example 2, the product of step c was characterized by NMR: Figure 4 As shown, the ratio of hyaluronic acid, o-phenylenediamine and Vc is 1:1:4.

[0072] 1H-NMR (D2O): Chemical shift δ1.90 (3H) is for the acetyl hydrogen of hyaluronic acid; δ6.8 (3H) is for the hydrogen on the benzene ring of o-phenylenediamine; Chemical shift δ=5.8, 6.4 (2H) is for the carbon-carbon double bond (CH=CH) peak of maleic acid; Chemical shift δ=4.6~4.7 is for the chemical shift of hydrogen (CH) on the Vc ring.

[0073] In Example 3, the product of step a was characterized by NMR: Figure 5 As shown, 1H-NMR (D2O): chemical shift δ6.8 (1H), 7.7 (2H) are hydrogens on the benzene ring of o-phenylenediamine. From the number of hydrogens, it can be seen that the molar ratio of hyaluronic acid and 3,4-diaminobenzoic acid methyl ester is 1:1.

[0074] NMR characterization of the product of step c: Figure 6 1H-NMR (D2O) shown: chemical shift δ1.96 (3H) is the acetyl hydrogen of hyaluronic acid; δ6.8 (3H) is the hydrogen on the benzene ring of o-phenylenediamine; chemical shift δ=5.8, 6.4 (2H) is the maleic acid carbon-carbon double bond (CH=CH) peak; chemical shift δ=4.6~4.7 is the chemical shift of hydrogen (CH) on the Vc ring.

[0075] Based on the number of hydrogen atoms in the characteristic nuclear magnetic resonance of hyaluronic acid, o-phenylenediamine, maleic acid and Vc, the nuclear magnetic resonance characterization of the final product of Example 3 showed that the ratio of hyaluronic acid, o-phenylenediamine and Vc was 1:1:4.

[0076] In Example 3, the product of step a is characterized by infrared spectrum, as shown in Figure 7 As shown, compared Fig. 9 Infrared spectrum characterization of hyaluronic acid. From the spectrum, we can see that 1550cm -1 ~1600cm -1 The left and right are the NH bending vibration spectra of the formed amide bond; 700 cm -1 ~800cm -1 is the out-of-plane bending vibration spectrum of the CH ring of benzene, 1210cm -1 ~1300cm -1 This is the CO stretching vibration spectrum of the ester group. The above data show that a new amide bond is formed. At the same time, it shows a spectrum containing a benzene ring and an ester group, which matches the structure of o-phenylenediamine benzoate.

[0077] Infrared spectrum of the product in step c, such as Figure 8 As shown in the spectrum, 1650cm -1 ~1700cm -1 The C=O stretching vibration and C=C olefinic stretching vibration spectra of the ester group, 1550cm -1 ~1600cm -1 The NH bending vibration spectrum of the formed amide bond is shown on the left and right, 1350 cm -1 -1450cm -1 For the CH vibration of cis-butene, 700cm -1 ~800cm -1 This is the out-of-plane bending vibration spectrum of the benzene ring CH, which matches the structures of o-phenylenediamine benzoate, maleic acid and Vc.

[0078] Example 4: Performance evaluation of the product prepared in Example 3

[0079] (1) Evaluation of injectability

[0080] Hyaluronic acid (HA) was dissolved in deionized water, and ultrasound was used to assist dissolution when necessary to prepare a series of blank HA solutions at different concentrations. The state of the blank HA solution was observed by inverting the vial. The prepared HA solution was inhaled by a 1 mL syringe (24G needle) and injected into an empty 5 mL sample vial. Its injectability was observed by taking a photo. The best concentration of HA was screened using injectability and viscosity as indicators. The results showed that when the concentration reached 20 mg / ml, it had good injectability and slightly poor viscosity. When the concentration reached 100 mg / ml, it had good viscosity characteristics and slightly poor injectability. At a concentration of 40-80 mg / ml, the HA solution had both good viscosity characteristics and injectability characteristics. Fig.10 As shown, the viscosity and injectability characteristics of 20-100 mg / ml HA solutions.

[0081] According to the molar ratio of hyaluronic acid in HA solution, the concentrations of hyaluronic acid solutions modified with o-phenylenediamine (ODP-HA), vitamin C (Vc-HA), and o-phenylenediamine and vitamin C (VHA) were converted to prepare grafted hyaluronic acid. The viscosity was observed by inverting the vial, and the injectability was observed by a 1mL syringe (24G needle). The optimal concentration was screened using injectability and viscosity as indicators.

[0082] The results show that after the grafting of o-phenylenediamine and / or Vc groups, the viscosity of hyaluronic acid is significantly improved. When the HA concentration is 40-80 mg / ml, the hyaluronic acid modified with o-phenylenediamine (ODP-HA), vitamin C (Vc-HA), o-phenylenediamine and vitamin C (VHA), if the HA concentration reaches 60-80 mg / ml, the prepared gel is highly viscous and difficult to inject. When the HA concentration is 40 mg / ml, the VHA concentration is 70 mg / ml, which is both injectable and viscous. Fig.11 shown.

[0083] (2) Investigation of the response and scavenging ability of grafted hyaluronic acid to reactive oxygen species in the microenvironment

[0084] The sulfate peptide colorimetric method was used to evaluate the response and scavenging ability of VHA to ROS. 24% Ti(SO4)2 and H2SO4 were dissolved in distilled water to prepare a Ti(SO4)2 precursor solution. 100μL and 1.0mM H2O2 were mixed with 100μL of HA, ODP-HA, Vc-HA, VHA, Vc, an aqueous solution of a physical mixture of Vc and HA (Vc+HA), and a blank water medium, respectively, incubated at 25°C for 30min, centrifuged at 12000rpm for 2min, 50μL of the hydrogel supernatant was collected, 100μL of the Ti(SO4)2 precursor solution was added, and the H2O2 concentration was measured at 405nm in a 96-well plate. The results showed that HA, ODP-HA and blank solutions did not show reactive oxygen species response and scavenging ability, while Vc, Vc-HA, Vc+HA and VHA all showed good reactive oxygen species response and scavenging ability, such as Fig.12 shown.

[0085] The above results prove that HA modified with Vc has a significant ability to scavenge active oxygen, the physical mixture of HA and Vc does not affect the scavenging ability of Vc to active oxygen, and the ODP with only grafted o-phenylenediamine functional group has no response and scavenging properties to active oxygen. Compared with the Vc group and the Vc+HA physical mixture group, VHA after chemical grafting modification has the same active oxygen response and scavenging ability, indicating that chemical grafting can effectively graft the Vc group onto the hyaluronic acid molecule, and the introduced o-phenylenediamine will not affect the response and scavenging ability of Vc to active oxygen.

[0086] (3) Investigation of the response and scavenging ability of grafted hyaluronic acid to nitric oxide in the microenvironment

[0087] The Griess method was used to evaluate the response and scavenging ability of VHA to NO. Preparation of NO saturated solution: NO stock solution was prepared by Cu and dilute nitric acid method, and the reaction mechanism was 3Cu+8HNO3(dilute)→3Cu(NO3)2+2NO↑+4H2O. The specific reaction operation was as follows: 200ml of dilute nitric acid (volume ratio 1:4) was added to a glass flask containing 12.7g of Cu flakes and heated with an alcohol lamp. Since O2 would quickly oxidize NO to generate NO2, all devices were degassed with nitrogen for 30 minutes to remove O2, and the formed gas passed through 30% NaOH solution twice to capture NO2 produced by the reaction of NO with trace amounts of O2. In order to obtain a saturated NO solution (1.8mM, 20℃) as a stock solution, 10ml of deoxygenated deionized water was bubbled with NO for 30 minutes and stored under NO gas. The stock solution for each experiment was freshly prepared and stored in a glass flask with a rubber septum.

[0088] The Griess method was used to evaluate the NO scavenging ability of different types of hyaluronic acid: 20 μL NO solution was added to 120 μL HA, ODP-HA, Vc-HA, VHA aqueous solution, and blank water medium and mixed. After incubation at 25°C for 30 min, the remaining NO concentration was measured using the Griess assay according to the reagent supplier's protocol. The results showed that HA, Vc-HA, and blank solution showed no NO response and scavenging ability, while ODP-HA and VHA both showed good NO response and scavenging ability. Fig.13 shown.

[0089] The above results prove that HA without grafting modification, blank medium and Vc-HA with only Vc functional group grafting modification have no response and scavenging properties to nitric oxide. There is no significant difference in nitric oxide response and scavenging ability between ODP-HA with only o-phenylenediamine grafted and VHA with both Vc and o-phenylenediamine chemically grafted, indicating that the introduction of Vc will not affect the response and scavenging ability of o-phenylenediamine group to NO, further proving that chemical grafting can effectively graft groups onto hyaluronic acid molecules, and the introduced Vc will not affect the response and scavenging ability of o-phenylenediamine to NO.

[0090] (4) Evaluation of the stability of hyaluronic acid materials after grafting

[0091] The stability of the carrier material was evaluated by the stability of the active oxygen scavenging ability. First, an aqueous solution of VHA and an aqueous solution containing a physical mixture of Vc and HA were prepared and stored at 4°C for 7, 4, 2, 1, and 0 days. The scavenging ability of the two groups of preparations on ROS was evaluated by the sulfate peptide colorimetric method, using the same method as above.

[0092] 24% Ti(SO4)2 and H2SO4 were dissolved in distilled water to prepare Ti(SO4)2 precursor solution. 100μL and 1.0mMH2O2 were mixed with 100μL VHA and 100μL Vc and HA mixed solution respectively, incubated at 25℃ for 30min, centrifuged at 12000rpm for 2min, 50μL of hydrogel supernatant was collected, 100μL of Ti(SO4)2 solution was added, and the H2O2 concentration was measured by absorbance at 405nm in a 96-well plate.

[0093] The results showed that the scavenging ability of the VHA group for active oxygen did not change significantly with the storage time, while the scavenging ability of the Vc and HA physical mixture group for active oxygen decreased significantly with the extension of the storage time, and there was basically no active oxygen scavenging ability after 1 day of storage. This proved that after the Vc group was grafted onto the HA monomer molecule, the oxidation rate of the Vc group could be significantly inhibited. The main mechanism was that there were multiple hydroxyl groups in the Vc molecule that were easily oxidized. Through chemical reactions, they condensed with the hydroxyl groups to play a placeholder role and reduce the oxidation probability, thereby improving the stability of the Vc group and the stability of the active oxygen capacity. Fig.14 shown.

[0094] (5) Evaluation of cell safety of grafted hyaluronic acid materials

[0095] Culture of mouse mononuclear macrophages (RAW 264.7): Take out the frozen cells and place them in a 37°C constant temperature water bath for thawing. After disinfection with 75% ethanol, place them in a clean bench for use. Take out the sterilized 15mL centrifuge tube, add 5mL DMEM culture medium (containing 10% fetal bovine serum, 100U / mL streptomycin and 100U / mL penicillin), and then add 1mL of thawed cell freezing solution to mix evenly. After centrifugation at 1500rpm for 5min, discard the supernatant. Add 5mL DMEM culture medium to resuspend the cells and transfer them to a T25 culture flask, add 5mL culture medium, and gently shake the culture flask in a cross shape to evenly distribute the cell resuspension. Then place the culture flask in a 5% CO2 incubator with a relative humidity of 95% and a temperature of 37°C for culture, and regularly replace fresh DMEM culture medium for culture and use.

[0096] Culture of arthritis synovial fibroblasts (MH7A cells): Take out the frozen cells and place them in a 37°C constant temperature water bath for thawing. After disinfection with 75% ethanol, place them in a clean bench for use. Take out the sterilized 15mL centrifuge tube, add 5mL DMEM culture medium (containing 15% fetal bovine serum, 100U / mL streptomycin and 100U / mL penicillin), and then add 1mL of thawed cell freezing solution to mix evenly. After centrifugation at 1500rpm for 5min, discard the supernatant. Add 5mL DMEM culture medium to resuspend the cells and transfer them to a T25 culture flask, add 5mL culture medium, and gently shake the culture flask in a cross shape to evenly distribute the cell resuspension. Then place the culture flask in a 5% CO2 incubator with a relative humidity of 95% and a temperature of 37°C for culture. Regularly replace fresh DMEM culture medium for culture and set aside.

[0097] RAW 264.7 and MH7A cell viability study: RAW 264.7 and MH7A cells cultured to a sufficient number were inoculated into 96-well plates, with 3 replicates per group, and placed in a 37°C, 5% CO2 incubator for 24 hours. The culture medium was discarded when the cell state was stable. HA solution, Vc-HA solution, ODP-HA solution, VHA solution and physical mixed (Vc+ODP+HA) solution with a concentration of 250μg / mL were prepared with the corresponding culture medium. The concentration of each group was calculated based on HA, and they were added to 96-well plates and incubated with the above cells. The same volume of DMEM was used as a blank control. After 24 hours, the survival rate of each cell was determined by CCK-8 method.

[0098] The results showed that after incubation with MH7A cells and RAW 264.7 cells for 24 hours, the cell activity of each group of solutions had no significant difference from that of the control group, and the cell survival rate of each group was greater than 95%, proving that the toxicity of each group of materials HA, Vc-HA, ODP-HA, and VHA to cells was negligible. Fig.15 , Fig.16 shown.

[0099] (6) Evaluation of the response and scavenging ability of grafted hyaluronic acid materials on nitric oxide in cells

[0100] A HA solution with a concentration of 250 μg / ml was prepared, and the concentration of HA was converted into Vc-HA, ODP-HA, VHA, and physical mixed group (Vc+ODP+HA). The concentration of NO in cells was detected by Griess method and inverted fluorescence microscope.

[0101] Griess method was used to measure NO concentration: RAW264.7 cells were cultured at 3.5×10 5The cells / well were seeded in a 24-well plate at a density of 1 μg / mL in DMEM and incubated overnight. The culture medium was replaced with fresh culture medium containing 1 μg / mL LPS. After incubation for 24 h, the cells were treated with DMEM culture medium with different formulations (i.e., culture medium with (1) Control+LPS(C), (2) HA, (3) ODP-HA, (4) Vc-HA, (5) VHA, (6) Vc+ODP+HA)) for another 24 h. The culture medium was collected and centrifuged (3 000 rpm, 10 min, 4°C), and the supernatant was used to quantify the NO content using the Griess kit (Beyotime Biotechnology) according to the instructions.

[0102] Inverted fluorescence microscope observation: RAW 264.7 cells were plated at 1×10 5 The cells were seeded on coverslips in 6-well plates at a density of 100 cells / mL and incubated at 37°C in DMEM. After overnight incubation, the medium was replaced with 1 μg mL -1 Fresh medium containing LPS was used to incubate the samples of different groups (1) Control (C), (2) C + LPS, (3) HA, (4) ODP-HA, (5) Vc-HA, (6) VHA, and (7) Vc + ODP + HA for another 24 h. After incubation, the sample medium was replaced with a medium containing 5 × 10 -6 The cells were incubated again for 20 min in fresh medium containing M DAF-FM DA (NO-specific fluorescent dye), and then washed three times with PBS. The cells were observed under an inverted fluorescence microscope, and the fluorescence intensity was statistically analyzed.

[0103] The results of the Griess method showed that the scavenging ability of ODP-HA, VHA and the physical mixture group (Vc+ODP+HA) on NO in the cell microenvironment reached about 50%, which was significantly different from the control group (***** in the figure represents P<0.0001), indicating that they had good scavenging ability, while there was no significant difference between VHA and ODP-HA and the physical mixture group (Vc+ODP+HA), and HA and Vc-HA had no NO scavenging ability. Fig.17 shown.

[0104] The results of fluorescence intensity analysis under an inverted fluorescence microscope showed that there was no significant difference in fluorescence intensity between ODP-HA, VHA and the physical mixed group (Vc+ODP+HA) and the control group, and the fluorescence intensity was significantly lower than that of the LPS group, indicating that ODP-HA, VHA and the physical mixed group (Vc+ODP+HA) all had good ability to scavenge NO in cells, while HA and Vc-HA had no NO scavenging ability. The NO scavenging ability of VHA was significantly different from that of HA and Vc-HA, as shown in Figure 2. Fig.18 and Fig.19As shown (*** represents P < 0.0001 in the figure).

[0105] (7) Evaluation of the response and scavenging ability of grafted hyaluronic acid materials on reactive oxygen species in cells

[0106] The reactive oxygen species probe DCFH-DA was used to detect the intracellular ROS scavenging ability of each group of materials. RAW264.7 cells were cultured at 1×10 5 The cells were seeded at a density of 100 cells / mL on a coverslip in a 24-well plate, and DMEM medium was added and incubated at 37°C. After overnight incubation, the medium was replaced with fresh medium containing 1 μg / mL LPS. After incubation for 24 h, different DMEM medium (i.e., (1) Control, (C), (2) C+LPS, (3) HA, (4) ODP-HA, (5) VC-HA, (6) VHA, (7) VC+ODP+HA) was used. After culturing for 24 h, DCFH-DA (10 μM, DMEM without fetal bovine serum) was added to each experimental group and incubated for 20 min. The fluorescence intensity was observed under an inverted microscope.

[0107] The results of fluorescence intensity analysis showed that there was no significant difference in fluorescence intensity between VC-HA, VHA and physical mixed group (Vc+ODP+HA) and control group, and the fluorescence intensity was significantly lower than that of LPS group, indicating that VC-HA, VHA and physical mixed group (Vc+ODP+HA) could effectively remove ROS in cells. Then the fluorescence intensity of ODP-HA and HA was significantly higher than that of control group, and there was no significant difference with LPS group, indicating that ODP-HA and HA groups had no ability to remove reactive oxygen species. VHA had significant difference in the ability to remove reactive oxygen species compared with ODP-HA and HA. Fig. 20 and Fig.21 As shown (*** represents P < 0.0001 in the figure).

[0108] VHA can scavenge both reactive oxygen species and nitric oxide and is stable. It has multiple effects than single vitamin C-modified hyaluronic acid and ODP-modified hyaluronic acid, and is more stable than the physical mixture group.

[0109] The above shows and describes the basic principles, main features and advantages of the present invention. However, the above is only a specific embodiment of the present invention, and the technical features of the present invention are not limited thereto. Any other implementation methods derived by any technician in the field without departing from the technical solution of the present invention should be included in the patent scope of the present invention.

Claims

1. A hyaluronic acid derivative or salt having dual response to nitric oxide and reactive oxygen species, characterized in that: The structure of the hyaluronic acid derivative is as shown in Formula I: The salt is a sodium salt, a potassium salt, a zinc salt or a calcium salt.

2. The method for preparing the hyaluronic acid derivative or salt according to claim 1, characterized in that: The method comprises the following steps: Step S1, dissolving hyaluronic acid in water, adding methyl 3,4-diaminobenzoate and a condensing agent, stirring for 6 to 30 hours at a temperature of 10 to 50° C. to cause a condensation reaction, and after the reaction is completed, dialysis purification and freeze-drying to obtain a product HA-o-phenylenediamine; the condensing agent is 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, wherein the molar ratio of hyaluronic acid, methyl 3,4-diaminobenzoate, 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride is 1:1 to 3:1 to 4:1 to 4; Step S2, dissolving the product HA-o-phenylenediamine with a solvent, adding a solution of maleic anhydride dropwise, heating at a temperature of 25-60° C. for esterification reaction for 6-30 hours, and after the reaction is completed, dialyzing and freeze-drying to obtain the product HA-o-phenylenediamine-maleic acid; wherein the molar ratio of HA-o-phenylenediamine to maleic anhydride is 1:1-5; Step S3, dissolving the product HA-o-phenylenediamine-maleic acid with a solvent and water, adding a condensing agent and vitamin C, stirring for 6 to 30 hours at a temperature of 10-50° C. to cause a condensation reaction, and after the reaction is completed, dialyzing and freeze-drying to obtain the product HA-o-phenylenediamine-maleic acid-Vc; the condensing agent is 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, wherein the molar ratio of the product HA-o-phenylenediamine-maleic acid, 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, and vitamin C is 1:1-5:1-5:1-5.

3. The method for preparing a hyaluronic acid derivative or salt according to claim 2, characterized in that: In step S2, the solvent is selected from one or more of dimethyl sulfoxide, dimethylformamide, and N-methylpyrrolidone.

4. A composition, characterized in that The invention comprises the hyaluronic acid derivative or salt according to claim 1.

5. A composition according to claim 4, characterized in that The composition is in the form of a gel-like aqueous solution.

6. Use of the hyaluronic acid derivative or salt according to claim 1 in the preparation of cosmetics or medicines having lubricating, anti-inflammatory, antioxidant or moisturizing effects.

Citation Information

Patent Citations

  • Hyaluronic acid derivative and preparation method thereof

    CN110467689A

  • L-vitamin C hyaluronate derivative and preparation method and application thereof

    CN113527537A

  • Reductive hyaluronic acid ester and preparation method thereof

    CN116410346A